Anticoagulation Associated (VKA & NOAC) Intracerebral Hemorrhage Clinical Trial
Official title:
German-wide Multicenter Analysis of Oral Anticoagulant-associated Intracerebral Hemorrhage - Part Two (RETRACE-II)
Intracerebral hemorrhage [ICH] is the most feared complication of oral anticoagulation [OAC], yet therapeutic strategies are limited reflected by overall weak guideline recommendations. Studies investigating acute interventions especially in patients with ICH taking non-vitamin-K-oral-anticoagulants [NOAC] remain inconclusive. Further, acute management issues in OAC-ICH patients (hematoma evacuation surgery, prevention of acute thromboembolic events, intraventricular fibrinolysis) still need to be investigated. Therefore, this observational study (RETRACE-II) represents the follow-up investigation to RETRACE (German-wide Multicenter Analysis of Oral Anticoagulant-associated Intracerebral Hemorrhage, study-period 2006-2010, NCT01829581), now spanning a study-period from 2011 until 2015 with 19 participating tertiary care centers nation-wide in Germany. Data pooling of the two RETRACE studies, altogether including more than 2500 patients treated at 22 centers over a 10 year period will allow statistically appropriate analyses of different outcomes.
Stroke in general is one of the leading causes for death and disability in the industrialized world. Cardiac thrombo-embolisms are the major contributor to ischemic infarction with atrial fibrillation [afib] being the most frequent underlying pathology. As the prevalence of afib is constantly increasing with the ageing population, its established therapy (oral anticoagulation with vitamin-K antagonists [VKA] or non-vitamin-K-oral-anticoagulants [NOAC]) will increase alongside. Therefore, rates of OAC-ICH are expected to increase simultaneously. OAC-ICH is associated with larger ICH-volumes, an increased frequency of hematoma enlargement, and worse clinical outcome as compared to primary spontaneous ICH. Nevertheless, only limited evidence exists regarding acute treatment strategies. For the prevention of hematoma enlargement in VKA-ICH a large observational cohort study (n=1176) for the first time identified a time window (<4h) and INR level (INR<1.3) within which reversal of altered coagulation may show reduced rates of hematoma enlargement (1). For NOAC-ICH only very small sized investigations or case reports are available to address this pressing question - how to reverse anticoagulation in NOAC-ICH. Existing data does not even allow appropriate description of NOAC-ICH patients in terms of hematoma characteristics, re-bleeding rates, neurologic severity or functional outcome. Due to this dilemma and without available antidotes (except for dabigatran) reversal strategies are intensely debated and evidence based guideline recommendations do not exist. Further important treatment approaches in ICH-care such as (i) hematoma evacuation surgery, (ii) early anticoagulation or prophylaxis of systemic thromboembolisms, (iii) intraventricular fibrinolysis, have not been investigated as this growing sub-population (increasing incidence) has been vastly excluded from randomized trials. Therefore, this observational cohort study (RETRACE-II) will try to strengthen the therapeutic evidence for OAC-ICH treatment by data-assessment of 19 nation-wide tertiary care hospitals in Germany. Patients will be identified from medical records by the diagnosis of ICH and concomitantly present intake of VKA (INR>1.5) or known intake of NOAC during a time period from 20011-2015. Only patients with ICH associated to OAC will be included, other secondary causes i.e. tumors, trauma, vascular malformations or aneurysms etc. will be excluded. Clinical data on demographics, medical history, pre-ICH medication exposures and laboratory results will be obtained by medical charts, institutional databases or prospective registries, supplemented by structured interviews or by review of available medical records at each individual institution. Patient-derived follow-up information will be corroborated by review of pertinent medical records. An estimated total number of greater 1000 patients will be reviewed for this investigation. In detail the following parameters will be evaluated: - prior medical history (including CHADS-VASC-Score, HAS-Bled Score, vascular risk factors), - functional status prior admission (mRS), - neurological admission status (NIHSS, GCS), - imaging characteristics, - time intervals: symptom onset until admission, imaging, therapy initiation, - mode of hemostatic therapy, - acute blood pressure management, - complications (hemorrhagic- or ischemic-events, infectious) and treatment (surgical treatment, mode of antithrombotic treatment or prophylaxis of systemic thromboembolism, intraventricular fibrinolysis, etc.), - mortality rates, - functional outcome (mRS). Participating Centers (upon Invitation): Klinikum Bad Hersfeld, Department of Neurology, Germany. HELIOS Klinikum Berlin-Buch, Department of Neurology, Germany. University Hospital Charité Berlin, Department of Neurology, Germany. Klinikum Dortmund, Department of Neurology, Germany. University of Dresden, Department of Neurology, Germany. Asklepios Klinik Hamburg Altona, Department of Neurology, Germany. Heidelberg University Hospital, Department of Neurology, Germany. University of Jena, Department of Neurology, Germany. Klinikum Koblenz, Department of Neurology, Germany. University of Cologne, Department of Neurology, Germany. University of Leipzig, Department of Neurology, Germany. Klinikum der Stadt Ludwigshafen am Rhein, Department of Neurology, Germany. Johannes Wesling Medical Center Minden, Department of Neurology, Germany. University of Münster, Department of Neurology, Germany. Klinikum Nürnberg, , Department of Neurology, Germany. Klinikum Stuttgart, Department of Neurology, Germany. University of Ulm, Department of Neurology, Germany. University of Wuerzburg, Department of Neurology, Germany. Funding: This study was partly supported by research grants from the Johannes & Frieda-Marohn Foundation (FWN/Zo-Hutt/2011) and from the ELAN fonds (ELAN 12.01.04.1), University of Erlangen, Germany. ;